Combining TIM3 and PD-1 inhibitors in preclinical studies has demonstrated enhanced immune restoration, as exhausted T cells in the tumor microenvironment commonly express both TIM3 and PD-1. This evidence concerns the gene HAVCR2 and neoplasm.